cancer
wildpixel / iStockphoto.com
5 September 2017Americas

Kite accused of infringing Juno’s cancer immunotherapy

Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
26 July 2017   Clinical-stage biotech company Juno Therapeutics has not taken kindly to another business using its name.
Americas
26 February 2018   Kite Pharma has entered into a collaboration with Sangamo Therapeutics that will see the companies develop next-generation engineered cell therapies to treat cancer.
Biotechnology
2 April 2020   A court has rejected Gilead’s attempt to overturn a $752 million verdict in a patent dispute with BMS’ Juno Therapeutics over CAR-T therapies.

More on this story

Americas
26 July 2017   Clinical-stage biotech company Juno Therapeutics has not taken kindly to another business using its name.
Americas
26 February 2018   Kite Pharma has entered into a collaboration with Sangamo Therapeutics that will see the companies develop next-generation engineered cell therapies to treat cancer.
Biotechnology
2 April 2020   A court has rejected Gilead’s attempt to overturn a $752 million verdict in a patent dispute with BMS’ Juno Therapeutics over CAR-T therapies.

More on this story

Americas
26 July 2017   Clinical-stage biotech company Juno Therapeutics has not taken kindly to another business using its name.
Americas
26 February 2018   Kite Pharma has entered into a collaboration with Sangamo Therapeutics that will see the companies develop next-generation engineered cell therapies to treat cancer.
Biotechnology
2 April 2020   A court has rejected Gilead’s attempt to overturn a $752 million verdict in a patent dispute with BMS’ Juno Therapeutics over CAR-T therapies.